Investors

Event Details

European Association for the Study of the Liver (EASL) Meeting

April 13, 2016

• Yurdaydin, C. et al; “Exploring optimal dosing of lonafarnib with ritonavir for the treatment of chronic delta hepatitis — results from the on-going LOWR HDV – 2 study.” Oral Presentation, Hepatitis Delta International Network (HDIN) at EASL • Dahari, H. et al; “Hepatitis delta virus (HDV) kinetics under the prenylation inhibitor lonafarnib suggest HDV-mediated suppression of the HBV replication.” Poster Presentation. • Dahari, H. et al; “Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.” Poster Presentation.